Impact of class I HDACs and their inhibitors on renal and colorectal tumor cell fate decisions

Nicole Kiweler
Advanced, metastasized renal and colorectal carcinomas are difficult to treat and frequently incurable diseases. Therefore, a key focus of modern cancer research is the identification of improved chemotherapeutic treatment options. Overexpression of histone deacetylases (HDACs) is a frequent characteristic of malignant neoplasms and often correlates with disadvantageous disease progression and therapy outcome. In recent years, inhibitors of histone deacetylases (HDACi) were introduced as a new class of small-molecule anticancer therapeutics. Since HDACs deacetylate numerous histones...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.